iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
CMS Sends Letter of Guidance to State Medicaid Programs & Letters to Pharma
 
 
  Download the PDF here
 
- "CMS will monitor state compliance with their approved state plans, the statue, and regulations to assure that access to these medications is maintained"
 
CMS Sends Letter of Guidance to State Medicaid Programs
addressing Resictions, Access, Discussing the federal applicable laws. Here are key summary points and the full letter below, pdf attached, and in full text below and immediately below key excerpts. Essentially, CMS has told states their practices regarding access to HCV treatment and restrictions are unreasonable and the state practices do not comply with federal law. Let's see how the states respond to this. CMS said medicaids must comply with the federal law, which says that states are required to provide access to medically necessary drugs, and that CMS will monitor their compliance. CMS refers to the Social Security Act and its Medicaid Rebate Program, which requires access for patients to newly approved drugs that are medically necessary without undue restrictions in order to get rebates. It appears they are saying the states are required to provide these treatments without the major restrictions imposed (F3;IDUs, specialists only), It appears CMS is saying FFS & MCO must provide the same access: a state medicaid cannot provide full access without restrictions through FFS and then less access/more restrictions through MCO. In the quote immediately below CMS says they will monitor the state policies to require the states comply with requirements of Federal Law - rebate agreements described in section 1927(b) of the Social Security Act (the Act) under their Medicaid fee-for-service (FFS) programs or Medicaid managed care plans are required to comply with the requirements of section 1927(d)(1) and (2) of the Act. CMS sent letters to 4 Hcv drug manufacturers, link to letters below, saying "The agency believes it is important that state Medicaid agencies have access to the lowest available manufacturer prices in the market"......"they should be given the opportunity to participate in discount or value-based purchasing arrangements offered by manufacturers. Therefore, CMS is interested in obtaining information from you about the challenges manufacturers face when offering these types of arrangements to state Medicaid agencies" ....the "Social Security Act (the Act) includes provisions to ensure that the Medicaid rebates for single source and innovator multiple source drugs are based, in part, on a manufacturer's "best price" for each covered outpatient drug...."Specifically, section 1927 of the Social Security Act (the Act) includes provisions to ensure that the Medicaid rebates for single source and innovator multiple source drugs are based, in part, on a manufacturer's "best price" for each covered outpatient drug ". And in reading the letter, which is the same to each company, CMS asks for feedback from each company on what they are doing to work with state medicaids 'to assist states in the affordability of these new, unbudgeted pharmaceuticals"
 
Jules Levin, NATAP
 
"CMS recognizes the challenges of defining policies in the face of new and innovative drug treatments. It will monitor the policies and conditions states impose for the coverage of DAA HCV drugs to ensure compliance with the requirements of the Act and access to effective, clinically appropriate, and medically necessary treatments for beneficiaries. CMS will monitor state compliance with their approved state plans, the statue, and regulations to assure that access to these medications is maintained."
 
FFS vs MCO
- "Consistent with the regulation at 42 CFR 438.210, services covered under Medicaid managed care contracts (with MCOs, prepaid inpatient health plans, and prepaid ambulatory health plans) must be furnished in an amount, duration, and scope that is no less than the amount, duration, and scope for the same services for beneficiaries under FFS Medicaid. While managed care plans may place appropriate limits on DAA HCV drugs using criteria applied under the state plan, such as medical necessity, the managed care plan may not use a standard for determining medical necessity that is more restrictive than is used in the state plan [FFS]. .....states should carefully monitor utilization controls and the HCV coverage policies of their managed care plans to ensure that the organizations are providing appropriate access to covered services and benefits consistent with 42 CFR 438.210"
 
"....limitations [restrictions] should not result in the denial of access to effective, clinically appropriate, and medically necessary treatments using DAA drugs for beneficiaries with chronic HCV infections. States should, therefore, examine their drug benefits to ensure that limitations do not unreasonably restrict coverage of effective treatment using the new DAA HCV drugs."
 
"Accordingly, to the extent that states provide coverage of prescription drugs, they are required to provide coverage for those covered outpatient drugs of manufacturers that have entered into, and have in effect, rebate agreements described in section 1927(b) of the Act, when such drugs are prescribed for medically accepted indications, including the new DAA HCV drugs......
CMS has sent a letter to the manufacturers of these DAA HCV drugs, asking them to provide information regarding any value-based purchasing arrangements they offer for these drugs so that states might be able to participate in such arrangements. .......the recent launch of multiple DAA HCV drugs in the marketplace is creating competition in this class that may result in downward pressure on the prices of these drugs. This competition may enhance the ability of states to negotiate supplemental rebates or other pricing arrangements with manufacturers to obtain more competitive prices for both their FFS and managed care programs, thereby reducing costs. CMS encourages states to take advantage of such opportunities......CMS is concerned that some states are restricting access to DAA HCV drugs contrary to the statutory requirements in section 1927 of the Act by imposing conditions for coverage that may unreasonably restrict access to these drugs. For example, several state Medicaid programs are limiting treatment to those beneficiaries whose extent of liver damage has progressed to metavir fibrosis score F3, while a number of states are requiring metavir fibrosis scores of F41.....Certain states are also requiring a period of abstinence from drug and alcohol abuse as a condition for payment for DAA HCV drugs....several states are requiring that prescriptions for DAA HCV drugs must be prescribed by, or in consultation with specific provider types, like gastroenterologists, hepatologists, liver transplant specialists, or infectious disease specialists in order for payments to be provided for the drug.....limitations should not result in the denial of access to effective, clinically appropriate, and medically necessary treatments using DAA drugs for beneficiaries with chronic HCV infections. States should, therefore, examine their drug benefits to ensure that limitations do not unreasonably restrict coverage of effective treatment using the new DAA HCV drugs......As such, the effect of such limitations should not result in the denial of access to effective, clinically appropriate, and medically necessary treatments using DAA drugs for beneficiaries with chronic HCV infections. States should, therefore, examine their drug benefits to ensure that limitations do not unreasonably restrict coverage of effective treatment using the new DAA HCV drugs. CMS encourages states to exercise sound clinical judgment and utilize available resources to determine their coverage policies "
 
-----------------------
 
Obama administration worries that some states are restricting access to costly hepatitis drugs - letters from CMS to states attached
 
By RICARDO ALONSO-ZALDIVAR
Associated Press
November 5, 2015
 
WASHINGTON - Confronting the consequences of high-priced drugs, the Obama administration Thursday pointedly reminded states that they cannot legally restrict access by low-income people to revolutionary cures for liver-wasting hepatitis C infection.
 
The federal Centers for Medicare and Medicaid Services also sent letters to several drug manufacturers, requesting details of what they are doing to make their medications more affordable. Among the companies getting federal letters was California based Gilead Sciences, maker of market-leading Harvoni.
 
The moves echoed government pressure decades ago to make sure that low-income people covered by federal-state Medicaid programs had access to ground-breaking HIV treatments. It's coming at a time the cost of prescription drugs is the leading health care issue for the public, according to opinion polls.
 
Hepatitis C is a viral illness that affects some 3 million people in the U.S. and claims more lives here than AIDS. Patients say it feels like a bad flu that never goes away. While the disease advances gradually, it can ultimately destroy the liver, requiring a transplant to save the patient's life.
 
Previous treatments were hit and miss, and many patients couldn't tolerate the side effects. With new drugs like Harvoni and Viekira Pak, patients finally have a choice among highly effective cures with minimal side effects. But with a course of treatment priced at around $100,000, the costs are straining government programs and private insurers alike.
 
In a notice to state Medicaid directors, the administration reminded states of their legal obligations to cover prescription medications for the poor.
 
Federal officials said they are concerned that some states are restricting access "contrary to ... statutory requirements" by "unreasonably" imposing limitations on which patients can get the new drugs.
 
They questioned requirements by some states that patients must have advanced liver disease first before they can get the cure. Since the new drugs cure hepatitis C, doctors say such restrictions don't make sense from a clinical perspective. Federal officials also cited requirements by some states that patients abstain from illegal drugs and alcohol as condition of getting treatment.
 
The administration also requested explanations from drug companies that make, or are working on, breakthrough treatments. Although Medicaid programs are entitled to substantial savings from drug makers, that hasn't been sufficient with the new hepatitis C drugs. Officials also asked for details on what the companies are doing to help states cover the cost of their medications.
 
----------------
 
HERE is link to letters sent to each of 4 HCV drug makers:
http://www.medicaid.gov/medicaid-chip-program-information/by-topics/benefits/prescription-drugs/hcv-communication.html.....in these letters they discuss pharma giving medicaid's the best prices.
 
-----------------
 
LETTER from CMS to State Medicaid Programs
November 5, 2015

cms.gif

MEDICAID DRUG REBATE PROGRAM NOTICE
 
ASSURING MEDICAID BENEFICIARIES ACCESS TO HEPATITIS C (HCV) DRUGS

 
The purpose of this letter is to advise states on the coverage of drugs for Medicaid beneficiaries living with hepatitis C virus (HCV) infections. Specifically, this letter addresses utilization of the direct-acting antiviral (DAA) drugs approved by the Food and Drug Administration (FDA) for the treatment of chronic HCV infected patients.
 
Rules Regarding Medicaid Drug Coverage

 
Coverage of prescription drugs is an optional benefit in state Medicaid programs, though all fifty (50) states and the District of Columbia currently provide this benefit. States that provide assistance for covered outpatient drugs of manufacturers that have entered into, and have in effect, rebate agreements described in section 1927(b) of the Social Security Act (the Act) under their Medicaid fee-for-service (FFS) programs or Medicaid managed care plans are required to comply with the requirements of section 1927(d)(1) and (2) of the Act.
 
Section 1927(d)(1) of the Act provides that a state may subject a covered outpatient drug to prior authorization, or exclude or otherwise restrict coverage of a covered outpatient drug if the prescribed use is not for a medically accepted indication as defined by section 1927(k)(6) of the Act, or the drug is included in the list of drugs or drug classes (or their medical uses), that may be excluded or otherwise restricted under section 1927(d)(2) of the Act.
 
Section 1927(k)(6) of the Act defines the term "medically accepted indication" as any use of a covered outpatient drug which is approved under the Food Drug And Cosmetic Act (FFDCA), or the use of which is supported by one or more citations included or approved for inclusion in any of the compendia described in section 1927(g)(1)(B)(i).
 
When establishing formularies, states must ensure compliance with the requirements in section 1927(d)(4), including the requirements of section 1927(d)(4)(C) of the Act. Under this provision, a covered outpatient drug may only be excluded with respect to the treatment of a specific disease or condition for an identified population if, based on the drug's labeling, or in the case of a drug the prescribed use of which is not approved under the FFDCA, but is a medically accepted indication based on information from the appropriate compendia described in section 1927(k)(6), the excluded drug does not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness, or clinical outcome of such treatment for such population over other drugs included in the formulary and there is a written explanation (available to the public) of the basis for the exclusion.
 
Accordingly, to the extent that states provide coverage of prescription drugs, they are required to provide coverage for those covered outpatient drugs of manufacturers that have entered into, and have in effect, rebate agreements described in section 1927(b) of the Act, when such drugs are prescribed for medically accepted indications, including the new DAA HCV drugs.
 
CMS is aware that, given the costs of these new DAA HCV drugs, states have raised concerns about the budgetary impact to their Medicaid programs and beneficiary access to needed care. The agency shares these concerns. However, the recent launch of multiple DAA HCV drugs in the marketplace is creating competition in this class that may result in downward pressure on the prices of these drugs. This competition may enhance the ability of states to negotiate supplemental rebates or other pricing arrangements with manufacturers to obtain more competitive prices for both their FFS and managed care programs, thereby reducing costs. CMS encourages states to take advantage of such opportunities.
 
To that end, manufacturers have a role to play in ensuring access and affordability to these medications. CMS has sent a letter to the manufacturers of these DAA HCV drugs, asking them to provide information regarding any value-based purchasing arrangements they offer for these drugs so that states might be able to participate in such arrangements.
 
Permissible Limitations to Medicaid Drug Coverage
 
CMS is concerned that some states are restricting access to DAA HCV drugs contrary to the statutory requirements in section 1927 of the Act by imposing conditions for coverage that may unreasonably restrict access to these drugs. For example, several state Medicaid programs are limiting treatment to those beneficiaries whose extent of liver damage has progressed to metavir fibrosis score F3, while a number of states are requiring metavir fibrosis scores of F41.
 
Certain states are also requiring a period of abstinence from drug and alcohol abuse as a condition for payment for DAA HCV drugs. In addition, several states are requiring that prescriptions for DAA HCV drugs must be prescribed by, or in consultation with specific provider types, like gastroenterologists, hepatologists, liver transplant specialists, or infectious disease specialists in order for payments to be provided for the drug.

 
While states have the discretion to establish certain limitations on the coverage of these drugs, such as preferred drug lists and use of prior authorization processes,2 such practices must be consistent with requirements of section 1927(d) of the Act to ensure appropriate utilization.
 
[2 In accordance with section 1927(d)(5) of the Act, a state plan may establish a prior authorization program as a condition of coverage or payment for a covered outpatient drug; however, the program must provide responses by telephone or other telecommunication device within 24 hours of a request for prior authorization, and, except for those drugs restricted or excluded from coverage pursuant to section 1927(d)(2) of the Act, provide for the dispensing of at least a 72-hour supply of a covered outpatient prescription drug in an emergency situation.]
 
As such, the effect of such limitations should not result in the denial of access to effective, clinically appropriate, and medically necessary treatments using DAA drugs for beneficiaries with chronic HCV infections. States should, therefore, examine their drug benefits to ensure that limitations do not unreasonably restrict coverage of effective treatment using the new DAA HCV drugs.
 
CMS encourages states to exercise sound clinical judgment and utilize available resources to determine their coverage policies. These resources include pharmacy and therapeutics (P&T) committees, drug utilization review (DUR) boards, and comparative analysis of the costs to treat HCV patients in light of the efficacy of these newer regimens in terms of cure rates, when compared to those of preexistent therapies. Additionally, CMS notes the availability of guidelines for states to refer to regarding testing, managing, and treating HCV put forth by the American Association for the Study of Liver Diseases (AASLD), the Infectious Diseases Society of America (IDSA), and the International Antiviral Society-USA (IAS-USA), which can be found at http://www.hcvguidelines.org/full-report-view. CMS also suggests that states consider implementing programs that provide patients on HCV treatment with supportive care that will enhance their adherence to regimens, thereby increasing the success rates.
 
Coverage under Medicaid Managed Care Plans
 
CMS is also concerned that in many states, Medicaid managed care organizations (MCOs) or other managed care arrangements' conditions for payment for DAA HCV drugs appear to be more restrictive than coverage under the states' fee-for-service (FFS) programs. Furthermore, in states with multiple MCOs or arrangements, the conditions for payment for DAA HCV drugs often differ between various plans.
 
CMS reminds states that the drugs under the approved state plan must be available to individuals enrolled in Medicaid managed care arrangements. As with their FFS program, states are urged to carefully monitor the DAA HCV drug coverage policies of their MCOs to ensure enrollees have appropriate access. States have the option to include these drugs in the managed care contracts and capitation rates or to "carve out" the drugs used in the treatment of chronic HCV
 
Consistent with the regulation at 42 CFR 438.210, services covered under Medicaid managed care contracts (with MCOs, prepaid inpatient health plans, and prepaid ambulatory health plans) must be furnished in an amount, duration, and scope that is no less than the amount, duration, and scope for the same services for beneficiaries under FFS Medicaid. While managed care plans may place appropriate limits on DAA HCV drugs using criteria applied under the state plan, such as medical necessity, the managed care plan may not use a standard for determining medical necessity that is more restrictive than is used in the state plan.
 
CMS recognizes the challenges of defining policies in the face of new and innovative drug treatments. It will monitor the policies and conditions states impose for the coverage of DAA HCV drugs to ensure compliance with the requirements of the Act and access to effective, clinically appropriate, and medically necessary treatments for beneficiaries. CMS will monitor state compliance with their approved state plans, the statue, and regulations to assure that access to these medications is maintained.
 
CMS shares with states the common goal of ensuring access to quality care for Medicaid beneficiaries. Given the complexities that have arisen with the introduction of the DAA HCV drugs, CMS will continue to work with State Medicaid agencies to continue providing and improving care to persons infected with chronic HCV infections. If you have any questions, please contact John M. Coster, Ph.D., R.Ph., Director of the Division of Pharmacy, at John.Coster@cms.hhs.gov.
 
Alissa Mooney DeBoy
Acting Director
Disabled and Elderly Health Programs Group

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org